Osprey Medical announced the launch of DyeMINISH; a global patient registry to evaluate the ongoing safety and performance of the DyeVert Contrast Reduction System during standard clinical use in a real-world patient population. The protocol includes the use of the DyeVert System, a device that assists in reducing the volume of potentially harmful contrast agents delivered to patients during the procedure.
The DyeMINISH registry is a retrospective, large-scale, multi-center study with the first patient included on May 7, 2019 at St. Elizabeth Healthcare in Edgewood, Kentucky by Dr. Mark Jordan, an Interventional Cardiologist. The registry is designed to enroll up to 10,000 participants and is expected to complete in late 2023.
“We are excited to be participating in the DyeMINISH Registry to help us evaluate our Contrast-Induced Acute Kidney Injury (CI-AKI) prevention protocol,” said Jordan in a news statement. “The multifaceted prevention protocol involves individualized assessment of patient’s risk of kidney injury, detailed preparation of the patient for the procedure, and efforts to limit exposure to imaging contrast volume. The registry will provide the framework and analytics we need to demonstrate improvements in patient care in our cath lab.”
The DyeMINISH Registry includes two study cohorts. The Core Study cohort is comprised of patients who underwent coronary or peripheral angiography imaging procedure with the DyeVert System. The Comparative Health Outcomes Sub-Study includes patients undergoing the same procedures without DyeVert that can be matched to a DyeVert Group patient via propensity score matching.
The Core Study aims to evaluate the use of imaging dye thresholds, actual imaging dye delivered to the patient and imaging dye saved. The Core Study also aims to evaluate the incidence of adverse events, such as the incidence of CI-AKI, the relationship between imaging dye and CI-AKI and other variables through to 120 days post-procedure.
The Comparative Health Outcomes Sub-Study will compare the difference in health outcomes between those patients who received DyeVert versus the no DyeVert control via measures which include kidney function, imaging dye use, and incidence of major cardiac and renal adverse events.
